Mechanistically, we also demonstrated that intraperitoneal TSA administration can suppress the activation of HDAC4 and downstream Akt, and attenuate the subsequent pulmonary fibrosis by inhibiting EMT. Here, HDAC4 is linked to pulmonary fibrosis.